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Abstract CYP102A1, originating from Bacillus megate-
rium, is a highly active enzyme which has attracted
much attention because of its potential applicability as
a biocatalyst for oxidative reactions. Previously we
developed drug-metabolizing mutant CYP102A1 M11 by a
combination of site-directed and random mutagenesis.
CYP102A1 M11 contains eight mutations, when compared
with wild-type CYP102A1, and is able to produce human-
relevant metabolites of several pharmaceuticals. In this
study, active-site residue 87 of drug-metabolizing mutant
CYP102A1 M11 was mutated to all possible natural amino
acids to investigate its role in substrate selectivity and
regioselectivity. With alkoxyresoruﬁns as substrates, large
differences in substrate selectivities and coupling efﬁcien-
cies were found, dependent on the nature of residue 87. For
all combinations of alkoxyresoruﬁns and mutants, extre-
mely fast rates of NADPH oxidation were observed (up to
6,000 min
-1). However, the coupling efﬁciencies were
extremely low: even for the substrates showing the highest
rates of O-dealkylation, coupling efﬁciencies were lower
than 1%. With testosterone as the substrate, all mutants
were able to produce three hydroxytestosterone metabo-
lites, although with different activities and with remarkably
different product ratios. The results show that the nature of
the amino acid at position 87 has a strong effect on activity
and regioselectivity in the drug-metabolizing mutant
CYP102A1 M11. Because of the wide substrate selectivity
of CYP102A1 M11 when compared with wild-type
CYP102A1, this panel of mutants will be useful both as
biocatalysts for metabolite production and as model pro-
teins for mechanistic studies on the function of P450s in
general.
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Introduction
Cytochrome P450 BM3 (CYP102A1; EC 1.14.14.1) from
Bacillus megaterium is a soluble protein that catalyzes the
hydroxylation and epoxidation of several long-chain fatty
acids. CYP102A1 contains a heme and reductase domain
fused in a single polypeptide, which might explain why this
enzyme has the highest activity ever reported for a P450
[1, 2]. By using site-directed and/or random mutagenesis,
several research groups have succeeded in broadening the
substrate selectivity of this enzyme with the objective to
create highly efﬁcient biocatalysts to be used for several
biotechnological applications [3–5]. In parallel, many
mechanistic studies have been devoted to rationalizing the
roles of various active-site residues in substrate selectivity
and in the catalytic cycle [1]. One of the most studied
active-site residues is Phe87, which is close to the heme
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DOI 10.1007/s00775-011-0789-4according to the crystal structures of CYP102A1 [1]. In the
substrate-free crystal, this residue lies perpendicular to the
heme at the end of the substrate-access channel. Upon
binding of substrate, the orientation of Phe87 changes to
parallel to the plane of the heme, thereby inﬂuencing the
orientation of the substrate relative to the catalytic center
[6]. Many studies have been performed in which Phe87 of
wild-type CYP102A1 or mutants of CYP102A1 has been
mutated to other amino acids, as summarized in Table 1.
Typically, in these studies one to maximally four different
mutations at position 87 were compared. In most cases,
Phe87 was mutated to amino acids with small nonpolar
side chains (Gly, Ala, Leu, Ile, Val), whereas only two
uncharged polar amino acids (Ser, Tyr) were evaluated.
Dependent on the substrate tested and the enzyme tem-
plate, the type of mutation of Phe87 has differential effects
on catalytic properties of P450 (Table 1), which are
rationalized by the changes in active-site volume, thereby
restricting or improving access to the reactive oxygen
species at the heme center [7–21].
Table 1 Effect of mutation of residue 87 on regioselectivity/stereoselectivity of wild-type and mutant CYP102A1
Mutation Template Substrate Effect References
F87G Wild type Lauric acid Less active; biphasic kinetics; changed regioselectivity [9, 19]
Wild type Propylbenzene, chlorostyrene More active; changed regioselectivity/stereoselectivity [11]
F87A Wild type Lauric acid, palmitic acid Less active; changed regioselectivity [7, 18, 19]
Wild type Farnesol More active; changed regioselectivity [18]
Wild type Fluoranthene, phenanthrene, pyrene More active; changed regioselectivity [10]
Wild type Propylbenzene Changed regioselectivity [11]
Wild type Chlorostyrene Less active; higher enantioselectivity [11]
Wild type (?)-Valencene Changed regioselectivity [21]
Wild type Resveratrol Less active [20]
A328I (?)-Valencene More active [21]
A328F Limonene More active [21]
R47L/Y51F (?)-Valencene Changed regioselectivity [14]
R47L/Y51F Resveratrol Less active [20]
9-10A Phenyl acetic acid esters, buspirone More active; higher enantioselectivity [16]
C(73-78) Lauric acid, palmitic acid, farnesol Less active [18]
C(75-80) Lauric acid, palmitic acid, farnesol Less active; unchanged regioselectivity [18]
C(78-82) Lauric acid, palmitic acid, farnesol Less active [18]
F87V Wild type Lauric acid Less active; changed regioselectivity [19]
Wild type Arachidonic acid, eicopentenoic acid Less active; changed regioselectivity [8]
Wild type Aromatic and phenolic compound More active; changed regioselectivity [15]
Wild type, A328L Geranyl acetone More active; changed regioselectivity [21]
A328I, A328V (?)-Valencene More active; changed regioselectivity [21]
R47L; R47L/L188Q Benzyloxyresoruﬁn and pentoxyresoruﬁn More active [13]
F87L Wild type Lauric acid Less active; changed regioselectivity [18]
Wild type Geranyl acetone Less active; changed regioselectivity [21]
A328I (?)-Valencene More active [21]
A328V Limonene, geranyl acetone Less active [21]
C(73-78); C(75-80) Lauric acid, palmitic, acid, farnesol Less active [18]
C(78-82) Lauric acid, palmitic acid Less active [18]
C(78-82) Farnesol More active; changed regioselectivity [18]
F87I Wild type Geranyl acetone More active; changed regioselectivity [21]
A328I (?)-Valencene More active [21]
A328V Geranyl acetone, limonene Less active [21]
F87S Wild type Lauric acid Changed regioselectivity [19]
F87Y Wild type Lauric acid Lower NADPH consumption; biphasic kinetics [9]
Wild type N-Palmitoyl glycine Inactive; 100% uncoupled [17]
Wild type Arachidonic acid, eicopentenoic acid Inactive; 100% uncoupled [8]
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123Recently, several CYP102A1 mutants have been devel-
oped with the ability to metabolize drugs to human-relevant
metabolites [4, 5]. These mutants typically contain eight to
ten mutations compared with wild-type CYP102A1,
including mutations of Phe87. One versatile mutant devel-
oped in our laboratory is CYP102A1 M11, which has been
constructed by a combination of site-directed mutagenesis,
introducing R47L, F87V, and L188Q, and three subsequent
rounds of random mutagenesis using four different alkoxy-
resoruﬁns as substrates to screen for improved enzyme
activity [5]. By the combination of eight mutations, when
compared with wild-type CYP102A1, CYP102A1 M11 has
acquired to ability to metabolize several drugs to high levels
of human-relevant metabolites and reactive intermediates of
drugs [22]. It would therefore be attractive to diversify this
versatile enzyme to variants with novel regioselectivities.
Because residue 87 plays a critical role in controlling sub-
strate selectivity in wild-type CYP102A1 and mutants of
CYP102A1 (Table 1), this residue was selected for muta-
genesis in the present study. Recently, mutation F87A was
shown to increase activity and enantioselectivity of buspi-
rone metabolism when applied to CYP102A1 mutant 10-9A
[16]. Other substitutions, however, were not evaluated. In
this study, all 20 natural amino acids were evaluated at
position 87 of CYP102A1 M11. Twelve of the possible
amino acid substitutions have not been described previously
in wild-type CYP102A1 or mutants of CYP102A1. The
mutants were characterized using a homologous series of
alkoxyresoruﬁns and testosterone as substrates. Alkoxyres-
oruﬁnsaresensitiveandusefulprobestodeterminesubstrate
selectivity of both bacterial and mammalian P450 isoforms
by the continuous ﬂuorimetric assay of resoruﬁn formed by
O-dealkylation [23–25]. Testosterone and other steroids
have been shownto be hydroxylated by CYP102A1 mutants
[26,27].Testosteroneisanexcellentprobesubstratetostudy
theeffectofposition87onregioselectivelybecauseitcanbe
hydroxylated at multiple positions dependent on the nature
ofP450isoenzymes[28].Furthermore,thereisgreatinterest
in biocatalysts capable of stereoselectively and regioselec-
tively hydroxylating steroids because steroid compounds
rank among the most widely marketed products from the
pharmaceutical industry [29]. We therefore studied whether
regioselectivity of steroid hydroxylation by CYP102A1 can
be manipulated by mutations at position 87.
Materials and methods
Materials
All chemicals were of analytical grade and obtained from
standard suppliers. Alkoxyresoruﬁns (methoxyresoruﬁn to
n-octoxyresoruﬁn) and benzyloxyresoruﬁn were synthe-
sized as described previously [24]. The pET28a? vector
containing wild-type CYP102A1 was kindly provided by
V. Urlacher (Institut fu ¨r Technische Biochemie, Universi-
ta ¨t Stuttgart, Germany).
Library construction
Site-directed mutants of CYP102A1 M11 at position 87
were constructed by mutagenic PCR using a Stratagene
QuikChange XL site-directed mutagenesis kit (Stratagene,
La Jolla, CA, USA) using 20 complementary pairs of
mutagenesis primers. The mutagenic PCR was applied to
a pBluescript vector (pBS p450 BM3 M11) containing the
gene of the drug-metabolizing CYP102A1 M11, ﬂanked
by EcoRI and BamHI restriction sites. CYP102A1 M11
contains mutations R47L, E64G, F81I, F87V, E143G,
L188Q, Y198C, E267V, H285Y, and G415S when com-
pared with wild-type CYP102A1 [10]. The sequence of
the forward primers was as follows: 50-GCA GGA GAC
GGG TTA XXX ACT AGT TGG ACG CAT-30. XXX
represents the codon that was used to introduce the spe-
ciﬁc mutation at position 87. The reverse primer for the
mutagenic PCR was a 34-mer 50-CAT GCG TCC AAC
TAG TYY YTA ACC CGT CTC CTG C-30 in which
YYY is the reverse complement of codon XXX. The
underlined bases indicate a new SpeI digestion site. The
following codons (XXX) were used: Ala GCC, Arg CGG,
Asn AAC, Asp GAC, Cys UGC, Gln CAG, Glu GAG,
Gly GGG, His CAC, Ile AUC, Leu CUG, Lys AAG, Met
AUG, Phe UUC, Pro CCC, Ser UCC, Thr ACC, Trp
UGG, Tyr UAC, and Val GUG.
After mutagenic PCR, the plasmids were digested
with EcoRI and BamHI restriction enzymes and the
genes of mutated CYP102A1 M11 were cloned into a
pET28a? vector, which encodes for an N-terminal His-
tag. The desired mutations in the P450 domain were
conﬁrmed by DNA sequencing (Baseclear, Leiden, The
Netherlands).
Expression and puriﬁcation of the mutants
Expression of the CYP102A1 mutants and wild-type
CYP102A1 was performed by transforming competent
Escherichia coli BL21 cells with the corresponding
pET28? vectors, as described previously [21]. Proteins
were puriﬁed using nickel nitrilotriacetic acid agarose,
after which P450 concentrations were determined
according to the method of Omura and Sato [30]. The
purity of the enzymes was checked by sodium dodecyl
sulfate polyacrylamide gel electrophoresis on 12% gel
and subsequent Coomassie staining.
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The enzyme activities of the mutants and wild-type
CYP102A1 toward a homologous series of alkoxyresoru-
ﬁns were measured according to the method of Burke et al.
[23] with modiﬁcations.To determine O-dealkylation
activities, ﬂuorescence cuvettes (1.5-mL volume) were
ﬁlled with 860 lL of 100 mM potassium phosphate buffer
(pH 7.4), 20 lLo f1lM CYP102A1 (20 nM ﬁnal con-
centration), and 20 lL of 1 mM alkoxyresoruﬁn in dime-
thyl sulfoxide (DMSO; ﬁnal concentrations 20 lM
alkoxyresoruﬁn, 2% DMSO). After 30 s of preincubation,
reactions were started by addition of 100 lL of a mixture of
2 mM NADPH, 3 mM glucose 6-phosphate, and 0.4 U/mL
glucose 6-phosphate dehydrogenase. The increase in ﬂuo-
rescence was monitored at an excitation wavelength of
532 nm and an emission wavelength of 586 nm for 2 min at
25 C. Speciﬁc activities were determined in triplicate by
measuring the initial slopes of resoruﬁn formation. The
Shimadzu RF-1501 spectroﬂuorometer used was calibrated
by addition of 10 lLo f1lM resoruﬁn to the cuvette and by
recording the increase in ﬂuorescence [23]. The results are
means of duplicate determinations, with duplicates typi-
cally differing by less than 5% from the mean.
To investigate involvement of hydroxylation of n-alkoxy
substituents at other carbons, 10 lL samples of incubations
were analyzed by an Agilent 2000 ultraperformance liquid
chromatography (UPLC) system using a Zorbax Eclipse
XDB-C18 column (1.8 lm, 50 mm 9 4.6 mm; Agilent,
USA). Samples were eluted at a ﬂow rate of 2 mL/min
using a gradient composed of solvent A (99.8% water, 0.2%
formic acid) and solvent B (99.8% acetonitrile, 0.2% formic
acid). The gradient was programmed as follows: from 0 to
1 min isocratic 40% solvent B, from 1 to 8 min linear
increase from 40 to 100% solvent B, from 8 to 8.5 min
isocratic 100% solvent B, from 8.5 to 9 min linear decrease
from 100 to 40% solvent B, from 9 to 10 min isocratic 40%
solvent B. Alkoxyresoruﬁns were detected at 460 nm.
Under these conditions the following retention times were
obtained: 2.84 min for methoxyresoruﬁn, 3.57 min for
ethoxyresoruﬁn, 4.20 min for n-propoxyresoruﬁn, 5.27 min
for n-butoxyresoruﬁn, 6.06 min for n-pentoxyresoruﬁn,
6.82 min for n-hexoxyresoruﬁn, 7.55 min for n-heptoxy-
resoruﬁn, and 8.21 min for n-octoxyresoruﬁn.
Metabolism of testosterone by CYP102A1 mutants
Incubations of CYP102A1 mutants (200 nM) with tes-
tosterone (0.5 mM) as the substrate were performed at
25 C in a total volume of 250 lL in 100 mM potassium
phosphate buffer (pH 7.4). Reactions were started by
adding 25 lL of a mixture of 2 mM NADPH, 3 mM
glucose 6-phosphate, and 4 U/mL glucose 6-phosphate
dehydrogenase (ﬁnal concentrations 0.2 mM NADPH,
0.3 mM glucose 6-phosphate, and 0.4 U/mL glucose
6-phosphate dehydrogenase), and were terminated after
60 min by addition of 250 lL cold methanol. Samples
were centrifuged for 15 min at 4,000 rpm, after which
supernatants were transferred to high-performance liquid
chromatography vials. Testosterone and metabolites were
analyzed by high-resolution UPLC [31] using an Agilent
2000 system using a Zorbax Eclipse XDB-C18 column
(1.8 lm, 50 mm 9 4.6 mm; Agilent, USA). Metabolites
and the substrate were eluted at a ﬂow rate of 1.3 mL/
min using a gradient composed of solvent A (99.8%
water, 0.2% formic acid) and solvent B (99.8% metha-
nol, 0.2% formic acid) The gradient was programmed as
follows: from 0 to 2 min linear increase from 60 to
100% solvent B, from 2 to 3 min isocratic 100% sol-
vent B, from 3 to 3.2 min linear decrease from 100 to
60% solvent B, from 3.2 to 5 min isocratic 60% solvent
B. Metabolites and the substrate were detected at
254 nm.
NADPH consumption
NADPH consumption was quantiﬁed spectroscopically by
monitoring the decrease in absorbance at 340 nm using an
extinction coefﬁcient of 6,210 M
-1 cm
-1. Cuvettes (1.5-
mL volume; 1 cm path length) were ﬁlled with 880 lLo f
100 mM potassium phosphate buffer (pH 7.4) and 20 lLo f
1 lM CYP102A1 mutant (ﬁnal concentration 20 nM).
Reactions were performed at 25 C and started by addition
of 100 lL of 2 mM NADPH (ﬁnal concentration 200 lM),
after which the decrease of NADPH was monitored for
2 min. To determine substrate-induced NADPH con-
sumption, cuvettes were ﬁlled with 860 lLo f1 0 0m M
potassium phosphate buffer (pH 7.4), 20 lLo f1 m M
alkoxyresoruﬁn (dissolved in DMSO), and 20 lLo f1lM
CYP102A1 mutant. Reactions were started by addition of
100 lL of 2 mM NADPH, after which the decrease of
NADPH was monitored for 2 min. To correct for the sol-
vent DMSO, incubations were also performed by adding
20 lL DMSO.
The coupling efﬁciencies of the CYP102A1 mutants
which were able to metabolize alkoxyresoruﬁns were cal-
culated from the ratio of the initial rate of product forma-
tion and the initial rate of NADPH consumption.
To investigate whether NADPH consumption is induced
by binding to the substrate binding site, incubations were
also performed in the presence of 1 lM ketoconazole,
which was shown to be a very potent inhibitor of
CYP102A1 mutants, including CYP102A1 M11 [13, 32].
To test whether wild-type CYP102A1 can also be inhibited
by ketoconazole, inhibition of NADPH consumption
induced by 100 lM lauric acid was studied.
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For a selection of the CYP102A1 mutants, the type of
substrate binding and the spectral dissociation constants
(KD) were determined for four substituted resoruﬁns
(methoxyresoruﬁn, n-butoxyresoruﬁn, n-heptoxyresoruﬁn,
and benzyloxyresoruﬁn) using UV–vis difference spec-
troscopy. UV–vis spectra were recorded at room tempera-
ture using a Shimadzu UV-2501PC spectrophotometer
(Shimadzu Duisburg, Germany). All substrate-induced
binding spectra were recorded using tandem cuvettes
(10-mm path length) to eliminate absorbance by alkoxy-
resoruﬁns. Brieﬂy, 1 mL of 2 lM enzyme in 100 mM
potassium phosphate buffer (pH 7.4) was added to one of
the chambers of the sample and reference tandem cuvette.
The other chambers were ﬁlled with an equal volume of
100 mM potassium phosphate buffer. The enzyme-con-
taining chamber of the sample cuvette was titrated with
microliter volumes of ethanol solutions of alkoxyresoru-
ﬁns, resulting in ﬁnal concentrations ranging from 1 to
30 lM. In the reference cuvette, the same volume of alk-
oxyresoruﬁn solution was added to the chamber containing
buffer only. To correct for effects of ethanol, equal vol-
umes of ethanol were added to the chambers without alk-
oxyresoruﬁn. At each concentration of substrate, a UV–vis
difference spectrum was recorded from 500 to 350 nm. The
observed differences in absorption between 390 nm (peak)
and 419 nm (trough), DA390–419, were plotted versus alk-
oxyresoruﬁn concentration after correction for dilution and
were analyzed by nonlinear regression using GraphPad
Prism 4 (GraphPad Sotware, San Diego, CA, USA). The
spectral dissociation constants (KD) were determined by
ﬁtting the titration binding curves using to the following
equation:
DA390 419 ¼
DA1  ½ S 
KD þ½ S 
where DA1 represents the maximal difference at saturating
alkoxyresoruﬁn concentration and KD is the dissociation
constant of the enzyme–substrate complex.
Results
Expression and characterization of the CYP102A1 M11
mutants
Transformation of E. coli BL21 with the pET28? vectors
encoding the different CYP102A1 M11 mutants and sub-
sequent puriﬁcation resulted in signiﬁcantly different
yields of CYP102A1 mutants, ranging from 27 to
666 nmol P450 per liter original growth medium (Table 2).
After puriﬁcation by nickel nitrilotriacetic acid agarose,
protein purity was always higher than 98% according to
sodium dodecyl sulfate polyacrylamide gel electrophoresis.
For four of the puriﬁed mutants containing Pro87, Asp87,
Glu87, and Ser87, the reduced CO difference spectra only
showed a peak at 420 nm. Formation of P420 is considered
to result from coordination of a neutral thiol (in the case of
CYP102A1 Cys400) to the heme iron, instead of a thiolate,
which is required to produce the active P450 [33]. Mutation
F87S, when applied to wild-type CYP102A1, was previ-
ously shown to be an active enzyme with changed regi-
oselectivity in lauric acid hydroxylation [19]. However,
CO difference spectroscopy only showed P420, suggesting
that Ser87 is denaturing owing to sodium dithionite treat-
ment (V. Urlacher, personal communication). Because the
concentration of these mutants could not be quantiﬁed, they
were not further evaluated in our metabolism experiments.
The mutant containing Asn87 showed a signiﬁcant peak at
420 nm with intensity almost equal to that at 450 nm.
Mutants containing Met87, His87, and Gly87 showed a
small shoulder at 420 nm next to the peak at 450 nm. All
other mutants only produced peaks with maxima ranging
from 448 and 450 nm.
Alkoxyresoruﬁn metabolism by the CYP102A1 M11
mutants
O-dealkylation activities
Table 3 shows that the speciﬁc activities of O-dealkylation
of nine different alkoxyresoruﬁns measured in incubations
with 16 variants of CYP102A1 M11 were very strongly
affected by the nature of the amino acid at position 87. On
average, thehighestO-dealkylationactivitieswere observed
with mutants containing nonpolar side chains Ala87, Gly87,
and Val87. Of the polar residues, Tyr87 was most active,
showingsigniﬁcantactivitywithallalkoxyresoruﬁns,except
with methoxyresoruﬁn as the substrate. The mutants con-
taining the charged residues only showed low activities
toward all alkoxyresoruﬁns. Under the present conditions,
Lys87, Met87, and Trp87 did not show signiﬁcant O-deal-
kylation activity with any alkoxyresoruﬁn.
When comparing O-dealkylation activity between the
different n-alkoxy-substituted substrates (methoxyresoruﬁn
to n-octoxyresoruﬁn), we found that the compounds with
the shortest n-alkoxy substituent were poorly metabolized.
Methoxyresoruﬁn was not O-demethylated by any of the
mutants, whereas for ethoxyresoruﬁn and n-propoxyres-
oruﬁn only two and three mutants, respectively, showed
activity. The longer the n-alkoxy group, the more enzymes
showed activity, although to very different extents. The
three most active mutants, Gly87, Ala87, and Val87,
and mutant Tyr87 all showed the highest activity with
n-pentoxyresoruﬁn as the substrate; both increasing and
J Biol Inorg Chem (2011) 16:899–912 903
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gradual decrease in activity. For the mutants with polar side
chains, which show low O-dealkylation activity, generally
the highest activity was found with the longer n-alkoxy
substituents (n-hexoxyresoruﬁn to n-octoxyresoruﬁn).
In addition to the n-alkoxy-substituted substrates, ben-
zyloxyresoruﬁn was used to characterize the different
mutants. As shown in Table 3, benzyloxyresoruﬁn is
O-alkylated at relatively high activity by several mutants
when compared with their activities toward the n-alkoxy-
resoruﬁns; for mutants Phe87, Leu87, Val87, Asn87, Gln87,
Tyr87, and Arg87 the highest O-dealkylation was observed
with this substrate. Similar to the n-alkoxy compounds, the
highest activities were found in the mutants of small non-
polar residues, with the highest activity in the case of
mutants containing Val87, Gly87, and Ala87.
The different alkoxyresoruﬁns were also incubated with
wild-type CYP102A1 containing a phenylalanine at posi-
tion 87. Consistent with our previous study [13], wild-type
CYP102A1 showed no O-dealkylation activity with most
alkoxyresoruﬁns. Only with n-heptoxyresoruﬁn and n-oct-
oxyresoruﬁn was a low but signiﬁcant resoruﬁn production
found.
To study whether long-chain alkoxyresoruﬁns are
hydroxylated at other positions of the n-alkoxy chain,
which would not result in O-dealkylation, incubations were
analyzed by UPLC with detection at 460 nm, which is the
absorption maximum of all alkoxyresoruﬁns, independent
of the nature of the n-alkoxy substituent. Chromatograms
of these incubations measured at 460 nm showed only
strong peaks of the unchanged alkoxyresoruﬁn substrates.
Only extremely small peaks (less than 3% of parent com-
pound) were found (data not shown), indicating that side-
chain hydroxylations did not occur to a signiﬁcant extent.
NADPH consumption and coupling efﬁciency
Table 4 shows the speciﬁc activities of the alkoxyresoruﬁn-
dependent NADPH consumption in incubations with
CYP102A1 M11 mutants and wild-type CYP102A1. The
incubation conditions were similar to those for the ﬂuori-
metric O-dealkylation assays, except that the NADPH-
regenerating system was excluded to enable NADPH
consumption to be measured. Surprisingly, all of the
mutants tested showed a very high speciﬁc activity in
NADPH consumption. The highest activities were found in
incubations with the mutant containing residue His87. This
mutant showed speciﬁc activities higher than 6,000 nmol
NADPH/min/nmol P450, leading to complete consumption
of NADPH within 4 min. The lowest activities were found
Table 2 Spectroscopic
properties and yields of the
CYP102A1 M11 mutants
ND no detectable peak at
450 nm, NQ not quantiﬁable
owing to the absence of a peak
at 450 nm
a CYP102A1 M11 containing
R47L, E64G, F81I, F87V,
E143G, L188Q, E267V, and
G415S [9]
No. Residue Reduced-CO difference spectra P450 yield (nmol/L
growth medium)
Maximum (nm) A450/A420 ratio
Nonpolar side chain
1 Phe87 450 [100 165
2 Gly87 423, 449 78 148
3 Ala87 449 [100 51
4 Leu87 449 [100 237
5 Ile87 449 [100 581
6 Val87
a 449 [100 666
7 Met87 423, 448 12.1 344
8 Pro87 420 ND NQ
9 Trp87 450 [100 27
Uncharged polar side chain
10 Ser87 422 ND NQ
11 Thr87 449 [100 203
12 Asn87 421, 450 1.2 132
13 Gln87 448 [100 49
14 Tyr87 448 [100 585
15 Cys87 450 [100 41
Charged polar side chain
16 Lys87 448 [100 91
17 Arg87 449 [100 173
18 His87 423, 450 5.8 80
19 Asp87 420 ND NQ
20 Glu87 420 ND NQ
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123in mutants containing residues Tyr87, Ile87, Leu87, and
Met87. Interestingly, for each mutant NADPH consump-
tion was more or less similar for the substrates with the
shorter n-alkoxy substituents, methoxyresoruﬁn to n-pent-
oxyresoruﬁn and allyloxyresoruﬁn. For each mutant, the
activities with these substrates varied by only 10–15%,
which is close to the analytical error. These results suggest
that for these alkoxyresoruﬁns, NADPH oxidation is not
inﬂuenced by the length of the n-alkoxy group. For sub-
strates with longer n-alkoxy substituents, n-hexoxyresoru-
ﬁn to n-octoxyresoruﬁn, NADPH oxidation gradually
decreased with increasing n-alkoxy chain length. Also, in
the case of benzyloxyresoruﬁn, having a bulky O-sub-
stituent, signiﬁcantly lower NADPH consumption was
observed than for the other substrates.
Because no signiﬁcant other metabolic pathways (side-
chain hydroxylation) were found, the coupling efﬁciencies
of the mutants were calculated from the ratio of the speciﬁc
activities of resoruﬁn production and NADPH consumption
(Table 5). Because of the very high rates of NADPH
consumption for all combinations of substrates and
enzymes, extremely low coupling efﬁciencies were found.
The highest coupling efﬁciencies were found with mutants
containing Ala87 and Val87, with the highest coupling
efﬁciencies of 0.68% (n-pentyl) and 0.75% (benzyl),
respectively. For most reactions, the coupling efﬁciencies
were too low to quantify because O-dealkylation activities
were below the limit of detection.
To test whether NADPH consumption induced by alk-
oxyresoruﬁn is the result of binding to the substrate binding
site, we investigated whether 1 lM ketoconazole was able
to block NADPH consumption in incubations of wild-type
CYP102A1 and mutant Val87 (M11). To test whether this
concentration of ketoconazole was able to inhibit
CYP102A1, we ﬁrst investigated whether it was able to
block NADPH consumption induced by 0.1 mM lauric
Table 3 Speciﬁc activities (nmol resoruﬁn/min/nmol P450) of alkoxyresoruﬁn O-dealkylation by CYP102A1 M11 mutants and wild-type
CYP102A1
No. Residue Side chain
Methyl Ethyl n-Propyl n-Butyl n-Pentyl n-Hexyl n-Heptyl n-Octyl Benzyl
Nonpolar side chain
1 Phe87 ND ND ND ND ND 0.11 0.16 0.060 0.29
2 Gly87 ND ND ND 1.01 3.80 2.59 0.74 0.14 4.02
3 Ala87 ND 0.16 1.53 4.37 11.05 1.83 0.34 0.10 3.79
4 Leu87 ND ND ND ND 0.042 0.024 0.051 0.024 0.23
5 Ile87 ND ND ND ND 0.35 0.010 0.062 ND 0.031
6 Val87
a ND ND 0.75 1.08 1.64 0.42 0.11 0.068 5.43
7 Met87 ND ND ND ND ND ND ND ND ND
8 Pro87 – – – – – – – – –
9 Trp87 ND ND ND ND ND ND ND ND ND
Uncharged polar side chain
10 Ser87 – – – – – – – – –
11 Thr87 ND ND ND 0.12 ND 0.10 0.055 0.060 0.12
12 Asn87 ND ND ND ND ND 0.021 0.053 0.057 0.14
13 Gln87 ND ND ND ND ND 0.077 0.097 0.064 0.51
14 Tyr87 ND 0.024 0.13 0.14 0.55 0.076 0.017 0.031 0.92
15 Cys87 ND ND ND ND ND 0.026 ND ND ND
Charged polar side chain
16 Lys87 ND ND ND ND ND ND ND ND ND
17 Arg87 ND ND ND ND ND 0.013 0.010 0.028 0.038
18 His87 ND ND ND ND ND 0.046 0.022 0.046 ND
19 Asp87 – – – – – – – – –
20 Glu87 – – – – – – – – –
21 Wild type (Phe87) ND ND ND ND ND ND 0.17 0.18 ND
Speciﬁc activities observed with 20 lM alkoxyresoruﬁn and 20 nM P450 BM3. THe values represent averages of three measurements, standard
deviations were less than 10%
ND not detectable (less than 0.01 nmol/min/nmol P450)
a CYP102A1 M11 containing R47L, E64G, F81I, F87V, E143G, L188Q, E267V, and G415S [22]
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123acid. With both wild-type CYP102A1 and mutant Val87,
lauric acid strongly stimulated NADPH consumption.
Addition of 1 lM ketoconazole completely blocked lauric
acid induced NADPH consumption of both enzymes.
When wild-type CYP102A1 and mutant Val87 (M11) were
tested with benzyloxyresoruﬁn as the substrate, ketocona-
zole was also able to almost completely block substrate-
induced NADPH consumption as well as the O-dealkylation
reaction (data not shown).
Binding spectra
Titration of alkoxyresoruﬁns to solutions of CYP102A1
and the two selected CYP102A1 M11 mutants in all cases
resulted in typical type I difference spectra with a peak at
390 nm and a trough at 419 nm (data not shown), indica-
tive of the conversion of the heme iron from low spin to
high spin. Table 6 shows the dissociation constants (KD)
obtained by nonlinear ﬁtting of the DA390–419 versus
substrate concentration curves, after correction for dilution.
Surprisingly, methoxyresoruﬁn, which is not O-demethy-
lated by any of the mutants, binds to the selected mutants
with relatively high afﬁnity with binding constants ranging
from 2.4 to 8 lM (Table 6). Because enzyme activity
measurements were carried out with 20 lM substrate, it
can be concluded that the lack of O-dealkylation is most
likely due to nonproductive binding rather than lack of
afﬁnity for the enzyme. Wild-type CYP102A1, which only
showed very low O-dealkylation activity toward n-hept-
oxyresoruﬁn, showed higher afﬁnity for the other alkoxy-
resoruﬁns which are not O-dealkylated. CYP102A1 M11
mutants containing Ala87 and Val87, which generally
showed relatively high O-dealkylation activity, showed
slightly higher afﬁnity for the alkoxyresoruﬁns than wild-
type CYP102A1. The only substrate showing signiﬁcantly
lower afﬁnity for wild-type CYP102A1 when compared
with the CYP102A1 mutants was n-heptoxyresoruﬁn
(Fig. 1).
Table 4 Speciﬁc activities (nmol NADPH/min/nmol P450) of alkoxyresoruﬁn-induced NADPH consumption by CYP102A1 M11 mutants and
wild-type CYP102A1
No. Residue Side chain DMSO
Methyl Ethyl n-Propyl n-Butyl n-Pentyl n-Hexyl n-Heptyl n-Octyl Benzyl
Nonpolar side chain
1 Phe87 4,100 4,590 3,640 4,520 4,290 3,120 1,150 370 2,170 \10
2 Gly87 4,380 3,910 3,950 4,440 4,170 2,200 960 300 2,360 105
3 Ala87 1,860 1,800 1,510 1,910 1,620 550 300 130 950 90
4 Leu87 1,180 1,120 960 1,110 540 260 270 190 190 95
5 Ile87 820 930 770 730 360 180 100 110 200 85
6 Val87
a 2,930 2,660 2,590 3,180 2,100 900 290 310 720 190
7 Met87 1,030 760 660 920 880 140 110 75 400 25
8 Pro87 – – – – – – – – – –
9 Trp87 2,090 1,790 1,450 1,880 1,980 870 320 130 1,450 45
Uncharged polar side chain
10 Ser87 – – – – – – – – – –
11 Thr87 1,910 1,570 1,530 1,900 1,890 800 470 260 480 \10
12 Asn87 3,260 2,950 2,450 2,920 2,970 1,530 730 250 2,260 \10
13 Gln87 1,860 1,740 1,510 1,770 1,920 700 420 200 1,130 40
14 Tyr87 700 680 620 710 690 400 130 87 370 \10
15 Cys87 3,570 3,490 3,030 3,430 3,470 1,590 560 150 2,370 35
Charged polar side chain
16 Lys87 3,570 3,400 3,080 4,100 3,780 1,580 600 210 2,220 \10
17 Arg87 3,740 3,780 2,950 3,400 2,970 840 240 97 1,330 25
18 His87 6,110 6,080 5,650 5,600 5,600 2,240 1,650 890 5,100 \10
19 Asp87 – – – – – – – – – –
20 Glu87 – – – – – – – – – –
21 Wild type (Phe87) 4,650 3,970 3,290 4,220 4,020 2,260 1,030 730 4,110 45
The values represent averages of three measurements; standard deviations were less than 10%
DMSO dimethyl sulfoxide
a CYP102A1 M11 containing R47L, E64G, F81I, F87V, E143G, L188Q, E267V, and G415S [22]
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123Testosterone hydroxylation by the CYP102A1 M11
mutants
Analysis of incubations of the CYP102A1 mutants with
testosterone by UPLC showed three major metabolites
were produced that were eluted at 0.93, 1.48, and 1.69 min.
These metabolites corresponded to the three hydroxytes-
tosterone metabolites previously observed with triple-
mutant CYP102A1 R47L/F87V/L188Q [26]. Figure 2
shows the chromatograms obtained after incubations of
testosterone with mutants containing residues Tyr87,
Ala87, Phe87, and Ile87, since they are representative of
Table 5 Coupling efﬁciency (%) of alkoxyresoruﬁn O-dealkylation by CYP102A1 M11 mutants and wild-type CYP102A1
No. Residue Side chain
Methyl Ethyl n-Propyl n-Butyl n-Pentyl n-Hexyl n-Heptyl n-Octyl Benzyl
Nonpolar side chain
1 Phe87 ND ND ND ND ND 0.004 0.014 0.016 0.013
2 Gly87 ND ND ND 0.023 0.091 0.118 0.077 0.047 0.170
3 Ala87 ND ND 0.101 0.229 0.682 0.333 0.113 0.077 0.399
4 Leu87 ND ND ND ND 0.008 0.009 0.019 0.013 0.121
5 Ile87 ND ND ND ND 0.097 0.006 0.062 ND 0.016
6 Val87
a ND ND 0.029 0.034 0.078 0.047 0.038 0.022 0.754
7 Met87 ND ND ND ND ND ND ND ND ND
8 Pro87 – – – – – – – – –
9 Trp87 ND ND ND ND ND ND ND ND ND
Uncharged polar side chain
10 Ser87 – – – – – – – – –
11 Thr87 ND ND ND 0.006 ND 0.013 0.012 0.023 0.025
12 Asn87 ND ND ND ND ND 0.001 0.007 0.023 0.006
13 Gln87 ND ND ND ND ND 0.011 0.023 0.032 0.045
14 Tyr87 ND 0.004 0.021 0.020 0.080 0.019 0.013 0.036 0.249
15 Cys87 ND ND ND ND ND 0.002 ND ND ND
Charged polar side chain
16 Lys87 ND ND ND ND ND ND ND ND ND
17 Arg87 ND ND ND ND ND 0.002 0.042 0.029 0.003
18 His87 ND ND ND ND ND 0.002 0.001 0.005 ND
19 Asp87 – – – – – – – – –
20 Glu87 – – – – – – – – –
21 Wild type (Phe87) ND ND ND ND ND ND 0.016 0.025 ND
Coupling efﬁciencies were calculated by the following formula: speciﬁc activity of resoruﬁn production (Table 3)/speciﬁc activity of NADPH
consumption (Table 4) 9 100%
ND not detectable (\0.001%)
a P450 BM3 M11 containing R47L, E64G, F81I, F87V, E143G, L188Q, E267V, and G415S [22]
Table 6 Alkoxyresoruﬁn binding by wild-type CYP102A1 and CYP102A1 M11 mutants
Substrate KD (lM)
a
Methoxyresoruﬁn n-Butoxyresoruﬁn n-Heptoxyresoruﬁn Benzyloxyresoruﬁn
CYP102A1 (wild type) 8.4 ± 1.4 1.6 ± 0.2 22 ± 6.4 2.7 ± 0.4
CYP102A1 M11 Ala87 4.0 ± 0.5 1.1 ± 0.1 4.9 ± 0.4 1.4 ± 0.3
CYP102A2 M11 Val87 2.4 ± 0.2 0.8 ± 0.1 1.4 ± 0.2 1.8 ± 0.3
a Dissociation constants were determined by difference spectroscopy using 2 lM enzyme in 100 mM potassium phosphate buffer, pH 7.4,
titrated with a solution of substrate. All substrates produced a type I binding spectrum with a peak at 390 nm and trough at 419 nm. The data for
the absorbance at 419 nm minus the absorbance at 390 were corrected for dilution and ﬁtted to an equation for a bimolecular association reaction
to obtain the dissociation constant
J Biol Inorg Chem (2011) 16:899–912 907
123the diversity in the metabolic proﬁles obtained. The
metabolite eluted at 1.48 min was previously identiﬁed as
16b-hydroxytestosterone (16b-OH-T) [26]. For structure
elucidation of the other metabolites, large-scale (50-mL)
incubations were performed for 3 h containing 250 nM
mutant Val87 (P450 M11), 500 lM testosterone, 0.2 mM
NADPH, and a regenerating system (0.3 mM glucose
6-phosphate and 0.4 U/mL glucose 6-phosphate dehydro-
genase). Metabolites were extracted by dichloromethane
and isolated by preparative high-performance liquid chro-
matography. Structure identiﬁcation was performed by a
combination of
1D-
1H,
1H-
1H double-quantum-ﬁltered
correlation spectroscopy,
1H-
13C heteronuclear single
quantum coherence,
1H-
13C heteronuclear multiple quan-
tum correlation,
1H-
13C heteronuclear multiple bond
correlation, and
1H-
1H nuclear Overhauser effect spec-
troscopy NMR experiments [34]. The metabolite eluted
at 0.93 min was identiﬁed as 15b-hydroxytestosterone
(15b-OH-T), whereas the metabolite eluted at 1.69 min
was identiﬁed as 2b-hydroxytestosterone (2b-OH-T).
These two metabolites were previously also identiﬁed by
similar NMR experiments as products formed in incuba-
tions of testosterone with houseﬂy cytochrome P450
(CYP6A1) [35]. Very minor metabolites were eluted at
1.85 and 1.95 min; however, the concentrations of these
metabolites were too low to allow structural assignment.
As shown in Table 7, all mutants were able to hydrox-
ylate testosterone with widely different activities and with
signiﬁcant differences in metabolic proﬁles. The most
active mutants were Tyr87, Val87, Thr87, Phe87, Ile87,
and Ala87 (in decreasing order); the other mutants showed
activities less than 10% of that of Tyr87. In general,
mutants having a very low activity with alkoxyresoruﬁns as
substrates also showed a low activity with testosterone as
the substrate, except for the mutants containing Phe87 and
Thr87, which showed relatively high activity of testoster-
one hydroxylation. Incubation of wild-type CYP102A1 did
not show formation of any metabolites.
Figure 3 shows the metabolic proﬁles of the mutants
ordered according to similarities in the metabolic proﬁles,
and by preference for hydroxylation of the D-ring (e.g.,
15b-hydroxylation and 16b-hydroxylation) versus the
A-ring (2b-hydroxylation). Numbers below the bars
represent the ratio of D-ring to A-ring hydroxylation as
calculated from the sum of peak areas of 15b-OH-T and
16b-OH-T, divided by the peak area of 2b-OH-T.
Mutants containing residues Ile87, Val87, Gly87, Tyr87,
Trp87, and Ala87 all showed a preference for hydroxyl-
ation of the D-ring of testosterone. For mutants containing
Val87, Gly87, Tyr87, and Trp87 very similar proﬁles were
Fig. 1 Structures and reactions
of substrates used to
characterize the CYP102A1
mutants. a Alkoxyresoruﬁn
O-dealkylation:
R is:
H (methoxyresoruﬁn),
CH3 (ethoxyresoruﬁn),
C2H5 (n-propoxyresoruﬁn),
C3H7 (n-butoxyresoruﬁn),
C4H9 (n-pentoxyresoruﬁn),
C5H11 (n-hexoxyresoruﬁn),
C6H13 (n-heptoxyresoruﬁn),
C7H15 (n-octoxyresoruﬁn),
C6H5 (benzyloxyresoruﬁn).
b Testosterone hydroxylation:
arrows indicate identiﬁed
positions of hydroxylation
Fig. 2 Ultraperformance liquid chromatography chromatograms
obtained after incubations of testosterone (0.5 mM) with a selection
of CYP102A1 mutants (200 nM), representing the diversity in
regioselectivity. 15b-OH-T 15b-hydroxytestosterone, 16b-OH-T
16b-hydroxytestosterone, 2b-OH-T 2b-hydroxytestosterone
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123obtained with 15b-OH-T as the major metabolite
(50–55%), and with 16b-OH-T and 2b-OH-T formed in
approximately equal amounts (20–25%). Compared with
these mutants, the mutant containing Ala87 and Ile87
showed remarkable differences in regioselectivity of
D-ring hydroxylation. The mutant containing Ile87 was the
only mutant having high selectivity for 16b-hydroxylation,
whereas the mutant containing Ala87 showed predomi-
nantly 15b-hydroxylation, in addition to signiﬁcant
2b-hydroxylation at the A-ring.
Mutants containing Phe87 and Thr87, which had rela-
tively high activity, showed 2b-OH-T as the major
metabolite, with lower amounts of 16b-OH-T and
the lowest amounts of 15b-OH-T. Similar results were
obtained with the much less active mutants with residues
Met87, Lys87, and Leu87. Mutants containing Cys87,
His87, Gln87, and Asn87 also showed the highest prefer-
ence for A-ring hydroxylation with 2b-OH-T as the major
metabolite. For three of these mutants, D-ring hydroxyl-
ation was only found at the 15b-position; for Asn87 no
signiﬁcant D-ring hydroxylation was observed.
Discussion
The role of the residue at position 87 has been investigated
in many studies using wild-type CYP102A1 and mutants
containing one or two other mutations (Table 1). These
studies are hampered by the fact that only a limited number
of substrates are accepted, such as medium-chain and long-
chain fatty acids and small terpenoid and aromatic sub-
strates. Also, so far only a limited number of amino acid
substitutions have been evaluated at position 87. By far
most studies have been performed with F87A and to a
lesser extent with F87V and F87L. When applied to mutant
9-10A, containing R47C, V78A, K94I, P142S, T175I,
A184V, F205C, S226R, H236Q, E252G, R255S, A290V,
and L353V, addition of mutation of F87A resulted in high
enantioselectivity in buspirone hydroxylation [16], show-
ing that residue 87 also has an important role in more
promiscuous mutants of CYP102A1. However, the effects
of other amino acid substitutions were not reported. In the
present study, the role of position 87 in controlling sub-
strate and regioselectivity of drug-metabolizing mutant
CYP102A1 M11 was evaluated by creation of mutants with
all 20 natural amino acids at this position. Twelve of the
amino acid substitutions had not been reported previously
in any CYP102A1 variant. To characterize the catalytic
properties of these novel mutants, nine different alkoxy-
resoruﬁns and testosterone were used as probe substrates.
As shown in Tables 3 and 7, very signiﬁcant different
rates of product formation were found between the differ-
ent mutants. In the case of alkoxyresoruﬁns as the sub-
strate, the mutant containing Phe87 only showed a very low
O-dealkylation activity with longer-chain alkoxyresoruﬁns
starting from n-hexoxyresoruﬁn, with activities similar to
that obtained with wild-type CYP102A1, which also con-
tains Phe87. The mutants with the small nonpolar amino
acids Gly87, Ala87, Val87, and Ile87 all showed much
higher O-dealkylation activities, with an optimal activity
with n-pentoxyresoruﬁn as the substrate (Table 3). As
summarized in Table 1, replacement of the bulky Phe87 in
wild-type CYP102A1 by these small amino acids also
showed generally an increased activity toward non-fatty
acid substrates. Furthermore, the fact that mutants
containing Val87, Leu87, and Ile87 showed large differ-
ences in activity toward n-alkoxyresoruﬁns, and strongly
Table 7 Total activity and unit of activity (nmol hydroxytestoster-
one/nmol P450/h) of testosterone hydroxylation by CYP102A1 M11
mutants and wild-type CYP102A1
No. Residue Metabolite formation
a
15b-OH-T 16b-OH-T 2b-OH-T Total
activity
a
Nonpolar side chain
1 Phe87 86 275 499 860
2 Gly87 31 13 12 56
3 Ala87 356 25 244 625
4 Leu87 2 9 35 46
5 Ile87 21 597 92 710
6 Val87
b 641 351 218 1,210
7 Met87 11 33 36 81
8 Pro87 – – – –
9 Trp87 15 6 8 29
Uncharged polar side chain
10 Ser87 – – – –
11 Thr87 126 367 557 1,050
12 Asn87 ND ND 35 35
13 Gln87 21 ND 119 140
14 Tyr87 625 288 337 1,250
15 Cys87 1 ND 4 5
Charged polar side chain
16 Lys87 3 9 13 25
17 Arg87 32 ND 33 65
18 His87 40 ND 135 175
19 Asp87 – – – –
20 Glu87 – – – –
21 Wild type (Phe87) ND ND ND ND
15b-OH-T 15b-hydroxytestosterone, 16b-OH-T 16b-hydroxytestosterone,
2b-OH-T 2b-hydroxytestosterone, ND not detectable
a Speciﬁc activities observed with 0.5 mM testosterone and 200 nM P450
BM3. The values represent averages of two measurements; variability was
always less than 10%
b CYP102A1 M11 containing R47L, E64G, F81I, F87V, E143G, L188Q,
E267V, and G415S [22]
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123different regioselectivity in testosterone hydroxylation,
demonstrates that even minor changes in amino acid
properties of the residue at position 87 can have a large
effect on catalytic properties.
It was proposed previously that replacement of the bulky
Phe87 by smaller nonpolar residues creates space for bulky
substrates, allowing better positioning with respect to the
activated oxygen species, and as a result higher activities
and coupling efﬁciencies [8, 10]. To test whether coupling
efﬁciencies were affected by amino acid 87 substitutions,
the ratio of product formation to NADPH consumption was
studied. As shown in Table 4, extremely high activities of
substrate-induced NADPH consumption were found with
all mutants and, unexpectedly, wild-type CYP102A1. For
the most active enzymes, the speciﬁc activities of NADPH
consumption were close to the high speciﬁc activities
found with wild-type CYP102A1 and lauric acid and ara-
chidonic acid as substrates [8, 9]. Because resoruﬁn was
the only product found, the coupling efﬁciency was always
less than 1% for all productive enzymes (Table 5). The fact
that 20 lM substrate resulted in complete depletion of
200 lM NADPH within 2–3 min indicates that NADPH
consumption resulted from a catalytic process in which the
substrate triggers NADPH consumption without being
converted, such as uncoupling or redox cycling in which
the substrate undergoes one-electron reduction followed by
autoxidation by molecular oxygen. Uncoupling of P450 is
still a poorly understood process, and is considered to result
from premature release of iron-bound molecular oxygen
before completion of the catalytic cycle, producing super-
oxide anion radical (one-electron reduction) or hydrogen
peroxide (two-electron reduction; ‘‘peroxide shunt’’) or by
reduction of the [FeO]
3? intermediate producing water
(oxidase pathway) [36, 37]. Factors which might determine
the mode of uncoupling are active-site hydration, which
might favor the peroxide shunt, and the position of the
substrate in the active site and/or a large distance from the
[FeO]
3? intermediate to the substrate [36, 37]. Because the
mutants contain amino acids at position 87 with different
polarities and size, different modes of uncoupling might
underlie the high NADPH consumptions observed in the
present study. An alternative mechanism which might
explain alkoxyresoruﬁn-induced NADPH reduction is
reduction of alkoxyresoruﬁn at the level of the reductase
domain. Previously it was shown that rat liver microsomal
NADPH-cytochrome P450 reductase was able to catalyze
redox cycling of resoruﬁn by one-electron reduction of the
quinoneimine moiety [38]. However, the fact that keto-
conazole was able to almost completely inhibit alkoxy-
resoruﬁn-induced NADPH consumption by wild-type
CYP102A1 and mutant Val87 does not support this alter-
native mechanism. Also, the fact that alkoxyresoruﬁns
produce type I binding spectra when titrated to CYP102A1
and CYP102A1 mutants (Table 6) indicates that these
substrates bind with relatively high afﬁnity to the substrate
binding site of these enzymes. These results strongly sug-
gest that alkoxyresoruﬁns bind to CYP102A1 at the active
site mainly in a nonproductive orientation. However, the
mechanism by which alkoxyresoruﬁns stimulated extre-
mely high NADPH consumption in the position 87 mutants
and wild-type CYP102A1 still remains to be elucidated.
Previously, several mutations of position 87 in wild-type
CYP102A1 were shown to change regioselectivity and
stereoselectivity of several reactions (Table 1). In this
study, testosterone was used as the substrate to characterize
the regioselectivity of the different mutants. It was found
that all mutants tested were able to catalyze testosterone
hydroxylation, although with widely different activities and
with different regioselectivities (Table 6). Only three dif-
ferent metabolites were formed in signiﬁcant amounts, as
was shown previously in incubations with the triple-mutant
of CYP102A1 containing mutations R47L, F87V, and
L188Q [26]. Interestingly, the mutant containing Phe87
appeared to be a relatively active enzyme, whereas the
Fig. 3 Effect of amino acid at
position 87 on regioselective
hydroxylation of testosterone by
CYP102A1 mutants. Bars
represent the percentage of
product relative to the total
amount of products. Numbers
below each bar represent the
ratio of D-ring hydroxylation
(sum of 15b-hydroxylation and
16b-hydroxylation) and
A-ring hydroxylation
(2b-hydroxylation)
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123wild-type CYP102A1, which also contains Phe87, was
completely inactive. Structural identiﬁcation of the
metabolites by NMR experiments revealed that two of the
metabolites result from hydroxylation of the D-ring, at
positions 15b and 16b; the third metabolite results from
hydroxylation of the A-ring at position 2b. Available
crystal structures of CYP102A1 indicate that its substrate
binding site is a long hydrophobic channel, with the heme
iron located at the bottom of this channel [6]. This might
explain why only the protons of the A-ring and D-ring of
testosterone might approach the reactive iron-oxo species
close enough to become hydroxylated. As shown in Fig. 3,
several mutants have a strong preference for D-ring
hydroxylation, whereas others prefer hydroxylation of the
A-ring. The mutant containing Ile87 catalyzes predomi-
nantly 16b-hydroxylation, whereas in the case of the clo-
sely related leucine amino acid testosterone hydroxylation
takes place predominantly as 2b-hydroxylation. Why these
relatively small changes in amino acid side chain have such
a large effect on regioselectivity remains to be established
however. Screening of over 200 microbial P450s [27] and
genetic engineering of bacterial P450s previously enabled
several other P450s to be identiﬁed that can catalyze
2b-hydroxylation and 15b-hydroxylation of testosterone
[27, 39]. Although several enzymes were shown to catalyze
16a-hydroxylation, so far no bacterial P450s have been
reported that can catalyze 16b-hydroxylation of steroids.
The present study shows that the CYP102A1 mutant con-
taining Ile87 is the ﬁrst mutant with high selectivity for
16b-hydroxylation.
As summarized in Table 1, by far most amino acid
substitutions at position 87 which have been reported
involved mutations of Phe87 to amino acids with small
nonpolar side chains. Only two amino acids (Tyr and Ser)
with uncharged polar side chains have been studied,
whereas charged polar side chains have not been evaluated.
Mutation F87Y, when applied to wild-type CYP102A1,
resulted in an unproductive enzyme when long-chain fatty
acids were used as the substrate [8, 9, 17]. The increased
polarity caused by the hydroxyl group at the phenyl ring of
Tyr87 was considered to restrict heme accessibility of the
fatty acid substrates, and as a result causes full uncoupling
[8]. In the present study the mutant containing Tyr87
appeared more active than that containing Phe87 with both
alkoxyresoruﬁns and testosterone as the substrate.
Although Ser87 was not evaluated because the CO differ-
ence spectrum only showed a P420 spectrum, the mutant
containing Thr87 showed a P450 spectrum, and was one of
the most active mutants with testosterone as the substrate
(Table 7). The other uncharged and charged polar amino
acids also showed enzyme activity, although this was
generally low when compared with the enzyme activity of
the nonpolar amino acids. However, the substrates used in
the present study were all uncharged substrates. Therefore,
it remains to be evaluated whether the mutants containing
polar amino acids at position 87 will have higher afﬁnity
and activity with charged and polar substrates.
In conclusion, the results of this study show that, con-
sistent with the results of studies performed with wild-type
enzyme, the nature of the amino acid at position 87 has a
strong effect on the activity and regioselectivity of drug-
metabolizing mutants of CYP102A1. Several amino acid
substitutions not previously evaluated were shown to be
dependent on the substrates tested, active enzymes with
different substrate and regioselectivity. Because of the
wide substrate selectivity of CYP102A1 M11 when com-
pared with wild-type CYP102A1, this panel of mutants will
be useful as biocatalysts for metabolite production. Fur-
thermore, these mutants might be valuable model proteins
for mechanistic studies on the function of P450s in drug
metabolism.
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